# QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML

> **NCT03365661** · PHASE2 · WITHDRAWN · sponsor: **Masonic Cancer Center, University of Minnesota**

## Conditions studied

- High-Risk Acute Myeloid Leukemia
- Treatment-Related Acute Myeloid Leukemia
- Secondary Acute Myeloid Leukemia
- Myelodysplastic Syndrome

## Interventions

- **BIOLOGICAL:** ALT-803

## Key facts

- **NCT ID:** NCT03365661
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-10-30
- **Primary completion:** 2023-01-01
- **Final completion:** 2023-01-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor halted study.
- **Last updated:** 2018-11-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03365661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03365661, "QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03365661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*